Skip to Content

COVID-19 Monoclonal Antibody Therapy

Presbyterian is offering monoclonal antibody therapy for the treatment of COVID-19 non-hospitalized patients, who have mild to moderate disease, and who are at high risk of progressing to severe COVID-19 and/or hospitalization. Current availability and prevalence of coronavirus variants will determine which monoclonal antibody is offered.

Notice: Due to the newest coronavirus variant, the New Mexico Department of Health has directed that we can only offer one type of monoclonal antibody (Sotrovimab). Also given the recent surge in coronavirus cases, and very limited Sotrovimab supplies from the federal government, patients will be prioritized by those who have several high-risk conditions. Examples of higher risk conditions include:

  • 65+ years old
  • pregnancy
  • obesity (BMI)
  • immunocompromised status
  • multiple chronic illnesses

If Sotrovimab supplies are unavailable and you are at high risk, alternative therapies may be offered. If monoclonal antibody therapies are unavailable at Presbyterian, they may be available at another location. See the National Infusion Center Association for all participating clinics with COVID-19 treatments.

Have you been diagnosed with COVID-19 in the past week?

If you have been diagnosed in the past week with COVID-19 and meet the requirements outlined below call us at 505-588-7766 to schedule an appointment for monoclonal antibody treatment.

Not sure if you qualify? Learn More



If you have any of the following life-threatening symptoms call 911 or go to the closest emergency department.

  • Bluish lips or face
  • Severe and constant pain or pressure in the chest
  • Extreme difficulty breathing (such as gasping for air or being unable to talk without catching your breath)
  • Severe and constant dizziness or lightheadedness
  • Serious disorientation (acting confused)
  • Unconscious or very difficult to wake up
  • Slurred speech or difficulty speaking (new or worsening)
  • Seizures



Frequently Asked Questions


Eligibility

Who is not eligible for this treatment?

You may not be eligible for this treatment if:

  • You do not have a positive COVID-19 test result (PCR or at home)
  • You have had symptoms for more than 10 days
  • You were previously hospitalized for COVID-19 infection in the past 90 days
  • You require more oxygen since you started feeling sick within the last 10 days
  • There is no supply of approved monoclonal antibody treatments available to administer

Who is eligible for this treatment?

To be eligible for this treatment, patients must:

  1. Have had a positive COVID-19 test (PCR or rapid antigen)
  2. Have had mild to moderate symptoms for less than 10 days
  3. Be 12 years of age or older*
  4. Weigh at least 88lbs (40kg)*
  5. Be at high risk for progressing to severe COVID-19 and/or hospitalization due to one (or more of the following:
    • Older age (age ≥65 years of age)
    • Obesity or being overweight
        • For example, BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts
    • Pregnancy
    • Chronic kidney disease
    • Diabetes
    • Immunosuppressive disease or immunosuppressive treatment
    • Cardiovascular disease, including congenital heart disease, or hypertension
    • Chronic lung diseases
        • For example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension
    • Sickle cell disease
    • Neurodevelopmental disorders or other conditions that confer medical complexity
        • For example, cerebral palsy, genetic or metabolic syndromes and severe congenital anomalies
    • Having a medical-related technological dependence
        • For example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)

Important
Other medical conditions or factors, such as race or ethnicity, may also place people at high risk for progression to severe COVID-19 and eligibility for monoclonal antibodies is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID, see the CDC website: People with Certain Medical Conditions


* Contact us to discuss treatment options for high-risk patients younger than age 12 and/or weighing less than 88 pounds, including infants.

Do I need to be an existing Presbyterian patient to receive monoclonal antibody therapy?

No, Presbyterian is evaluating all COVID-19 patients in need of treatment. However, treatment is limited to those who qualify and if there is supply available. Please be aware there may be costs associated with the treatment depending on your insurance.

Do I need a provider referral for this treatment?

While Presbyterian prefers a provider referral, we understand the need to be treated as soon as possible. For this reason, a Presbyterian infusion provider will work with patients who qualify to make sure they are treated in a timely fashion.

General Information

What is monoclonal antibody therapy?

This treatment is an infusion of monoclonal antibodies, which are man-made antibodies that mimic the natural immune system’s ability to fight viruses. The medication works by blocking the virus from attaching to human cells and stopping it from causing further infection.

What are the benefits of the treatment?

Clinical trials for monoclonal antibody therapy have shown that patients who receive the treatment are about 70% less likely to be hospitalized or go to the emergency room. There is also a decrease in the amount of virus in an infected person’s blood which may help improve current symptoms. Studies are still ongoing.

Which treatments are offered?

There are three monoclonal antibody therapies that have been granted an Emergency Use Authorization by the FDA. There is no information to show that one is better than the other. The infusion center will provide the therapy they have available.

Are these treatments FDA approved?

No, these treatments are still considered investigational and were granted an Emergency Use Authorization (EUA) by the FDA. When issuing an EUA, the FDA evaluates the available scientific evidence and carefully balances any known or potential risks with any known or potential benefits for use during an emergency. Based on the FDA’s review, it granted an EUA for these monoclonal antibody therapies because they are believed to benefit certain patients. There are no other approved treatments for patients who qualify.

How is the therapy given?

It is administered in a vein by intravenous (IV) infusion. It is given in an infusion center where health care providers have immediate access to medications to treat any reactions and where emergency services are available, if needed.

How long will the treatment take?

The intravenous infusion takes about 30 minutes followed by 1 hour of observation time. The entire appointment (check-in/registration, infusion, observation time, etc.) takes about 2-3 hours.

Where is this treatment offered?

Within Presbyterian, the treatment is offered at seven locations throughout the state, including Albuquerque, Santa Fe, Española, Socorro, Clovis, Ruidoso, and Tucumcari. Please call us at 505-588-7766 to schedule an appointment.

For Referring Providers

How do I refer a patient for this therapy?

Any New Mexico physician or advanced practice clinician can refer a patient for monoclonal antibody therapy.

Once you have determined that your patient is eligible for treatment:

Presbyterian Provider (with PHS Epic access)

External Provider (no PHS Epic access)

  • Download, print, and complete this two-page referral form
    Provider Referral
  • Fax the referral form and other required documents, to Presbyterian Infusion Services at 505-563-1015.
    Other required documents include:
    • Fax coversheet from referring provider’s primary practice
    • Patient demographics (patient name, DOB, address, insurance, primary language)
    • Copy of most recent clinical encounter (e.g. history and physical, progress note, telephone note, video appointment note)
    • Copy of positive COVID-19 test result. If a copy of the test result is not available, mitigating reasons must be noted.
      PLEASE NOTE: Treatment will not be provided unless positive COVID-19 test result is confirmed.

Providers: If you have questions regarding eligibility of your patient, please call 505-563-1024.

Which patients are eligible for this therapy?

Adult and pediatric patients with positive results of direct SARS-CoV-2 viral testing (PCR or rapid antigen) who are 12 years of age and older, weigh at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Some patients less than age 12 or less than 40 kg may be eligible for therapy. Please contact your local Infusion Center to discuss.

The monoclonal antibody therapy should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. Patients are not eligible for treatment if >10 days from symptom onset. Treatment generally takes two to three hours in one single session. Not all infusion locations may be able to facilitate monoclonal antibody pediatric infusions; please call your local site to confirm.

To be eligible for this treatment, patients must:

  1. Have had a positive COVID-19 test (PCR or rapid antigen)
  2. Have had mild to moderate symptoms for less than 10 days
  3. Be 12 years of age or older*
  4. Weigh at least 88lbs (40kg)*
  5. Be at high risk for progressing to severe COVID-19 and/or hospitalization due to one (or more of the following:
    • Older age (age ≥65 years of age)
    • Obesity or being overweight
        • For example, BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts
    • Pregnancy
    • Chronic kidney disease
    • Diabetes
    • Immunosuppressive disease or immunosuppressive treatment
    • Cardiovascular disease, including congenital heart disease, or hypertension
    • Chronic lung diseases
        • For example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension
    • Sickle cell disease
    • Neurodevelopmental disorders or other conditions that confer medical complexity
        • For example, cerebral palsy, genetic or metabolic syndromes and severe congenital anomalies
    • Having a medical-related technological dependence
        • For example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)

Important
Other medical conditions or factors, such as race or ethnicity, may also place people at high risk for progression to severe COVID-19 and eligibility for monoclonal antibodies is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID, see the CDC website: People with Certain Medical Conditions


* Contact us to discuss treatment options for high-risk patients younger than age 12 and/or weighing less than 88 pounds, including infants.

Which patients are NOT eligible for this therapy?

Patients are not eligible if they:

  • have previously been hospitalized due to COVID-19
  • require oxygen therapy due to COVID-19
  • require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related co-morbidity

Where can my patients get this treatment?

Within Presbyterian, the treatment is offered at seven locations throughout the state, including Albuquerque, Santa Fe, Española, Socorro, Clovis, Ruidoso, and Tucumcari. Please call us at 505-588-7766 to confirm availability and hours of operation.